5.52
+0.25(+4.74%)
Currency In USD
| Previous Close | 5.27 |
| Open | 5.27 |
| Day High | 5.53 |
| Day Low | 5.25 |
| 52-Week High | 21.79 |
| 52-Week Low | 4.93 |
| Volume | 227,408 |
| Average Volume | 177,416 |
| Market Cap | 209.96M |
| PE | -2.72 |
| EPS | -2.03 |
| Moving Average 50 Days | 6.65 |
| Moving Average 200 Days | 11.45 |
| Change | 0.25 |
If you invested $1000 in Entrada Therapeutics, Inc. (TRDA) since IPO date, it would be worth $230.48 as of August 18, 2025 at a share price of $5.52. Whereas If you bought $1000 worth of Entrada Therapeutics, Inc. (TRDA) shares 3 years ago, it would be worth $427.91 as of August 18, 2025 at a share price of $5.52.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
GlobeNewswire Inc.
Jun 03, 2025 11:00 AM GMT
Maha Radhakrishnan, MD Maha Radhakrishnan, MD BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. “We are pleased to have Dr
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Jun 02, 2025 8:30 PM GMT
BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 23,820 restricted stock units (“RSUs”) to six newly-hired non-executive employees under the Company’s 2025
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
GlobeNewswire Inc.
May 28, 2025 11:00 AM GMT
– Company on track to begin ELEVATE-45-201 in Q3 2025 – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-45-201 – BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Entrada Therap